11 results
6-K
EX-99.1
LEGN
Legend Biotech Corp
13 Sep 21
Legend Biotech Corporation 6-K
9:02am
in patients with relapsed or refractory PTCL or CTCL (NCT04712864). Recruitment in the trial has begun in the U.S.
“We are excited by the promise of LB1901
6-K
LEGN
Legend Biotech Corp
13 Sep 21
Legend Biotech Corporation 6-K
9:02am
syndrome). Recruitment in the trial has begun in the U.S. The primary objectives are to characterize the safety and tolerability of LB1901
20-F
jphct
2 Apr 21
Annual report (foreign)
8:10am
424B4
pv5vpkpja 3bkrozspow
8 Jun 20
Prospectus supplement with pricing info
9:07am
F-1/A
xdbq3e
29 May 20
Registration statement (foreign) (amended)
8:32am
F-1
gv7eymy2y23
13 May 20
Registration statement (foreign)
4:41pm
DRS/A
thmvrbph0tiftrxn ff
8 May 20
Draft registration statement (amended)
12:00am
DRS/A
o3s96 dr2
20 Apr 20
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next